Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18362362 | 0.93 | NR1D1 (0.33) | NR1D1NR1H3 | |
| SCHEMBL6534869 | 0.91 | STING1 (0.33) | STING1 | |
| SCHEMBL17177620 | 0.90 | TSHR (0.32) | NR1D1 | |
| SCHEMBL1404485 | 0.90 | TDP1 (0.39) | STING1 | |
| Hydrochloric Acid SCHEMBL6840669 | 0.89 | MEN1 (0.34) | STING1 | |
| SCHEMBL2185396 | 0.89 | NR1D1 (0.35) | NR1D1NR1H3 | |
| Hydrochloric Acid SCHEMBL6840742 | 0.87 | NR1D1 (0.34) | NR1D1NR1H3 | |
| SCHEMBL8412077 | 0.86 | NR1D1 (0.34) | NR1D1NR1H3 | |
| SCHEMBL2185399 | 0.83 | TDP1 (0.43) | NR1D1NR1H3 | |
| SCHEMBL21548073 | 0.83 | NR1D1 (0.33) | NR1D1NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217621-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2015-04-22 | — | — | EP | disclosed |
| US-8710000-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-04-29 | — | — | US | disclosed |
| US-20100279931-A1 | Insulin Derivative | NOVO NORDISK A/S | 2010-11-04 | — | — | US | disclosed |
| EP-2217621-A1 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060071-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | WO | disclosed |
| EP-2058330-A1 | Insulin derivative | NOVO NORDISK A/S (DK) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279931-A1 | Insulin Derivative | IAPP, INSR, GPR119 | STING1 3481/4885NR1D1 730/4885NR1H3 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.